Kiromic BioPharma Inc KRBP shares are gaining Wednesday morning. However, there is no specific news today. During the session, the share price reached $9.22.
Monday morning, the FDA authorized the company's Investigational New Drug (IND) application to initiate a Phase 1 trial to evaluate Deltacel (KB-GDT-01) for patients with non-small cell lung cancer (NSCLC).
The company expects to start the trial in Q2 of 2023.
Deltacel is the company's allogeneic, non-engineered, off-the-shelf Gamma Delta T-cell therapy.
The company submitted the IND application in early April.
Kiromic BioPharma stock is gaining on heavy volume, with a session volume of 3.6 million shares traded, compared to the trailing 100-day volume of 164.038K shares.
According to data from Benzinga Pro, KRBP has a 52-week high of $24.9 and a 52-week low of $2.59.
Price Action: KRBB shares are up 45.70% at $5.20 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
